Investors on the quest for market-beating returns often employ the strategy of stock picking. Making informed choices in stocks can greatly amplify your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The closing price of Clover Health Investments Corp (NASDAQ: CLOV) was $3.19 for the day, up 1.27% from the previous closing price of $3.15. In other words, the price has increased by $1.27 from its previous closing price. On the day, 4.48 million shares were traded. CLOV stock price reached its highest trading level at $3.2265 during the session, while it also had its lowest trading level at $3.05.
Ratios:
Our analysis of CLOV’s different ratios will help us gain a deeper understanding of the company. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.01.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Craig Hallum on December 17, 2024, initiated with a Buy rating and assigned the stock a target price of $6.
On October 07, 2024, UBS started tracking the stock assigning a Neutral rating and target price of $4.
Cowen Upgraded its Underperform to Market Perform on February 02, 2022, whereas the target price for the stock was revised from $7 to $3.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Aug 09 ’24 when Garipalli Vivek bought 531,700 shares for $1.88 per share. The transaction valued at 999,596 led to the insider holds 1,409,267 shares of the business.
Garipalli Vivek bought 877,567 shares of CLOV for $1,000,426 on Jun 17 ’24. The Director now owns 877,567 shares after completing the transaction at $1.14 per share. On May 16 ’24, another insider, Loengard Anna U, who serves as the Director of the company, bought 17,085 shares for $0.96 each. As a result, the insider paid 16,372 and bolstered with 15,600 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CLOV now has a Market Capitalization of 1598537728 and an Enterprise Value of 1266536832. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.04 while its Price-to-Book (P/B) ratio in mrq is 4.51. Its current Enterprise Value per Revenue stands at 0.599 whereas that against EBITDA is -16.43.
Stock Price History:
Over the past 52 weeks, CLOV has reached a high of $4.71, while it has fallen to a 52-week low of $0.61. The 50-Day Moving Average of the stock is -11.56%, while the 200-Day Moving Average is calculated to be 51.20%.
Shares Statistics:
CLOV traded an average of 7.17M shares per day over the past three months and 4610500 shares per day over the past ten days. A total of 394.44M shares are outstanding, with a floating share count of 377.31M. Insiders hold about 24.71% of the company’s shares, while institutions hold 16.39% stake in the company. Shares short for CLOV as of 1732838400 were 15276865 with a Short Ratio of 2.13, compared to 1730332800 on 18329869. Therefore, it implies a Short% of Shares Outstanding of 15276865 and a Short% of Float of 3.7600000000000002.
